Objectives To investigate the effects of High-Flux Hemodialysis (HFHD) on Serum Hepcidin and Hypoxia Inducible Factor (HIF) in Maintenance Hemodialysis (MHD) Patients. Methods Sixty MHD patients in the First People's Hospital of Kunming Blood Purification Center between May 2018 and April 2020 were randomly divided into the HFHD group and the Low Flux Hemodialysis (LFHD) group (30 patients in each group). Pre- and post-dialysis whole blood specimens were collected from both groups at the beginning of the trial, 6 months into the trial, 12 months into the trial, and 18 months into the trial respectively. The differences in serum hepcidin, Hypoxia Inducible Factor (HIF), Interleukin-6 (IL-6), and Tumor necrosis factor-α (TNF-α) were examined and compared between the two groups. Results The hepcidin level : ①There was a statistically significant difference (Z=-2.927,P=0.003) between the HFHD group and the LFHD group [31.5 (21.4, 54.2) vs. 49.1 (36.9, 68.8)] at 18 months. ② There was a statistical difference of serum hepcidin at different time points in the HFHD group (H=50.992,P＜0.001) and the lowest at 18 months. Hypoxia Inducible Factor (HIF): The results were not statistically different (P＞0.05) between the HFHD and LFHD groups at each time point (Z=-1.442，-1.952，-0.834 and -3.152，P=0.149，0.051，0.404 and 0.912) or between different time points of the same group (H=13.212 and 6.369，P=0.808 and 0.095), and no significant trend over time was found. When compared between the two groups, IL-6 and TNF-α were lower in the HFHD group than in the LFHD group at 18 months (Z=-1.996, P=0.046, Z=-4.140,P＜0.001). Conclusion The effects of HFHD and LFHD on HIF were not significant. Compared with LFHD, HFHD decreased the levels of hepcidin, the levels of inflammatory factors IL-6 and TNF-α in patients with MHD which probably due to the preferential clearance of serum hepcidin and inflammatory factors by high-flux dialysis membranes, also improved the microinflammatory state in patients, thus reducing the high expression of hepcidin in the liver.
JIANG Xiao-Lan
,
LIU Bin
. Effect of high-flux hemodialysis on serum hepcidin and hypoxia-inducible factor in maintenance dialysis patients[J]. Chinese Journal of Blood Purification, 2023
, 22(02)
: 81
-85
.
DOI: 10.3969/j.issn.1671-4091.2023.02.001
[1] 陆再英, 钟南山. 内科学(第七版)[M]. 北京:人民卫生出版社, 2008: 567．
[2] 中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2014修订版)[J]. 中华肾脏病杂志, 2014, 30(9):712-716.
[3] 严震文, 简桂花, 盛蔚文, 陈伟军, 肖婧, 叶志斌, 汪年松. 慢性肾衰竭患者血清Hepeidin水平改变[J]. 老年医学与保健, 2010, 16(1):28-32.
[4］Knutson MD. Iron transport proteins: Gateways of cellular and systemic iron homeostasis[J]. Journal of Biological Chemistry, 2017, 292(31):12735-12743.
[5] 刘骏峰, 丁峰, 顾勇. 高通量透析研究新进展[J]. 中国血液净化, 2014, 4(13):317-320.
[6] 陈静, 朱蕊, 戴兵, 叶朝阳, 胡小红. 高通量血液透析与常规血液透析联合血液透析滤过治疗血液透析患者的生活质量评分比较[J]. 中国血液净化, 2016, 15(11): 609-611.
[7] Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension[J]. Proc Natl Acad Sci USA, 1995, 92(12):5510-5514．
[8] Nangaku M, Rosenberger C, Heyman SN, Eckardt KU.. Regulation of hypoxia-inducible factor in kidney disease[J]．Clin Exp Pharmacol Physiol, 2013, 40(2):148-157．
[9] Chopra T, Rosner MH. Recent advances in CKD and ESRD: A literature update[J]. Hemodialysis International, 2017, 21(1) :11-18.
[10] Locatelli F, Fishbane S, Block GA , Macdougall IC. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients[J]. American Journal of Nephrology, 2017, 45(3): 187-199.
[11] Arunava Kali, Marie Victor Pravin Charles, Rathan Shetty Kolkebail Seetharam. Hepcidin A novel biomarker with changing trends[J]. Pharmacogn Rev, 2015, 9 (17):35-40．
[12] 林善锬. 慢性肾脏疾病贫血[M]. 中国协和医科大学出版社. 2019.
[13] Zhang DL, Rouault TA. How does hepcidin hinder ferroportin activity?[J]. Blood, 2018, 131(8): 840-842.
[14] Young B, Zaritsky J. Hepcidin for clinicians[J]. Clin J Am Soc Nephrol, 2009, 4(8):1384-1387.
[15] Babitt JL, Herbert YL. Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD[J]. Am J Kidney Dis, 2010, 55(4):726-741.
[16] Ganz T, Nemeth E. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease[J]. Semin Nephrol, 2016, 36(2):87-93.
[17] Nakanishi T,Hasuike Y,Otaki Y,et a1. Hepeidin:an-other culprit for complications in patients with chronic kidney disease[J]. Nephrol Dial Transplant,2011,26 (10):3092-3100．
[18] Ueda N, Takasawa K.Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease[J]. Nutrients, 2018,10(9):1173-1205.
[19] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版)[J]. 中华肾脏病杂志, 2018, 34(11):860-866.
[20] Komaba H, Tanaka M, Fukagawa M. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Internal Medicine, 2008, 47(11):989-994.
[21] Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease[J]. Acta Haematologica, 2019, 142(1):44-50.
[22] Ribeiro S, Belo L, Reis F, Santos-Silva A. Iron therapy in chronic kidney disease: recent changes, benefits and risks[J]. Blood Reviews, 2016, 30(1):65-72.
